232 related articles for article (PubMed ID: 29677684)
1. Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus?
Tan J; Asthagiri Arunkumar G; Krammer F
Curr Opin Immunol; 2018 Aug; 53():45-50. PubMed ID: 29677684
[TBL] [Abstract][Full Text] [Related]
2. Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.
Moser MJ; Hatta Y; Gabaglia C; Sanchez A; Dias P; Sarawar S; Kawaoka Y; Hatta M; Neumann G; Bilsel P
Vaccine; 2019 Jul; 37(32):4533-4542. PubMed ID: 31280945
[TBL] [Abstract][Full Text] [Related]
3. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
[TBL] [Abstract][Full Text] [Related]
4. Influenza vaccines: 'tailor-made' or 'one fits all'.
Saletti G; Gerlach T; Rimmelzwaan GF
Curr Opin Immunol; 2018 Aug; 53():102-110. PubMed ID: 29734023
[TBL] [Abstract][Full Text] [Related]
5. Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.
Asthagiri Arunkumar G; Ioannou A; Wohlbold TJ; Meade P; Aslam S; Amanat F; Ayllon J; García-Sastre A; Krammer F
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626682
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model.
Ermler ME; Kirkpatrick E; Sun W; Hai R; Amanat F; Chromikova V; Palese P; Krammer F
J Virol; 2017 Jun; 91(12):. PubMed ID: 28356526
[TBL] [Abstract][Full Text] [Related]
7. Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
Piepenbrink MS; Nogales A; Basu M; Fucile CF; Liesveld JL; Keefer MC; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
mBio; 2019 Mar; 10(2):. PubMed ID: 30862743
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B.
Sugaya N; Nerome K; Ishida M; Matsumoto M; Mitamura K; Nirasawa M
JAMA; 1994 Oct; 272(14):1122-6. PubMed ID: 7933325
[TBL] [Abstract][Full Text] [Related]
9. Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance.
Skowronski DM; Hamelin ME; Janjua NZ; De Serres G; Gardy JL; Rhéaume C; Bouhy X; Boivin G
PLoS One; 2012; 7(6):e38929. PubMed ID: 22745690
[TBL] [Abstract][Full Text] [Related]
10. Cross-reactive antibodies induced by a monovalent influenza B virus vaccine.
Levandowski RA; Gross PA; Weksler M; Staton E; Williams MS; Bonelli J
J Clin Microbiol; 1991 Jul; 29(7):1530-2. PubMed ID: 1885750
[TBL] [Abstract][Full Text] [Related]
11. Development of an Alternative Modified Live Influenza B Virus Vaccine.
Santos JJS; Finch C; Sutton T; Obadan A; Aguirre I; Wan Z; Lopez D; Geiger G; Gonzalez-Reiche AS; Ferreri L; Perez DR
J Virol; 2017 Jun; 91(12):. PubMed ID: 28381580
[TBL] [Abstract][Full Text] [Related]
12. Prospects for broadly protective influenza vaccines.
Treanor JJ
Vaccine; 2015 Nov; 33 Suppl 4():D39-45. PubMed ID: 26338145
[TBL] [Abstract][Full Text] [Related]
13. Influenza B viruses: not to be discounted.
van de Sandt CE; Bodewes R; Rimmelzwaan GF; de Vries RD
Future Microbiol; 2015; 10(9):1447-65. PubMed ID: 26357957
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.
Belshe RB; Coelingh K; Ambrose CS; Woo JC; Wu X
Vaccine; 2010 Feb; 28(9):2149-56. PubMed ID: 20003926
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity.
Kirkpatrick E; Henry C; McMahon M; Jiang K; Strohmeier S; van Bakel H; Wilson PC; Krammer F
J Virol; 2020 Nov; 94(23):. PubMed ID: 32907980
[TBL] [Abstract][Full Text] [Related]
16. Epitope-focused vaccine design against influenza A and B viruses.
Ren H; Zhou P
Curr Opin Immunol; 2016 Oct; 42():83-90. PubMed ID: 27343703
[TBL] [Abstract][Full Text] [Related]
17. How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines.
Rudraraju R; Mordant F; Subbarao K
J Infect Dis; 2019 Apr; 219(Suppl_1):S81-S87. PubMed ID: 30715386
[No Abstract] [Full Text] [Related]
18. Development of next generation hemagglutinin-based broadly protective influenza virus vaccines.
Nachbagauer R; Palese P
Curr Opin Immunol; 2018 Aug; 53():51-57. PubMed ID: 29680576
[TBL] [Abstract][Full Text] [Related]
19. Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference.
Bandell A; Woo J; Coelingh K
Expert Rev Vaccines; 2011 Aug; 10(8):1131-41. PubMed ID: 21854309
[TBL] [Abstract][Full Text] [Related]
20. Broadly Reactive Influenza Antibodies Are Not Limited by Germinal Center Competition with High-Affinity Antibodies.
Keating R; Johnson JL; Brice DC; Labombarde JG; Dent AL; McGargill MA
mBio; 2020 Nov; 11(6):. PubMed ID: 33144374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
